Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06347809 · ClinicalTrials.gov registry record
DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in Urine
A clinical trial, sponsored by Mayo Clinic.
- Terminated
- Registry status
- 24
- Enrollment target
NCT06347809: Clinical Trial study, sponsored by Mayo Clinic.
NCT06347809 is a clinical trial that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06347809 was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- 24 participants
- Enrollment target
Study Summary
This study explores the potential use of DNA markers in the detection of prostate cancer and patient perceptions of this screening approach and other current or future prostate cancer screening and diagnostic tests.
Primary Outcome
Assessed by instances of CAP detected using MDMs assayed from urine (Phase I) and from urine and prostate fluid (collected following digital prostate massage for participants in Phase II) for detection of CAP.
Interventions
- OTHER Non-Interventional Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-01-23 |
| Est. Completion | 2025-07-31 |
Why NCT06347809 stopped before completion
NCT06347809 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 24 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06347809 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06347809 about?
NCT06347809 is a clinical study titled "DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in Urine". This study explores the potential use of DNA markers in the detection of prostate cancer and patient perceptions of this screening approach and other current or future prostate cancer screening and diagnostic tests.
What is the current status of trial NCT06347809?
This trial is currently terminated. The enrollment target is 24 participants. The study started on 2019-01-23. Estimated completion is 2025-07-31.
What interventions are being tested in trial NCT06347809?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06347809?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI